Differentiation of pheochromocytoma PC 12 cells induced by human urine extract and the involvement of the extracellular signal-regulated kinase signaling pathway

Journal of Alternative and Complementary Medicine

Volumn 11, Issue 5, 2005, Pages 903-908

  Yao, Chih Jung ^a   Lai, Gi Ming ^a   Chan, Chin Feng ^a   Yang, Ya Yu ^a   Liu, Frank C ^a   Chuang, Shuang En ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANTINEOPLASTIC AGENT; CDA 2; MITOGEN ACTIVATED PROTEIN KINASE; NERVE GROWTH FACTOR; UNCLASSIFIED DRUG; URINE EXTRACT;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL STRAIN; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; NEUROFILAMENT; NONHUMAN; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION; ADRENAL TUMOR; ANIMAL; CHEMICALLY INDUCED DISORDER; CHINESE MEDICINE; DRUG EFFECT; HUMAN; METABOLISM; PATHOLOGY; URINE; WESTERN BLOTTING;

ADRENAL GLAND NEOPLASMS; ANIMALS; BLOTTING, WESTERN; CELL DIFFERENTIATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MEDICINE, CHINESE TRADITIONAL; PC12 CELLS; PHEOCHROMOCYTOMA; RATS; SIGNAL TRANSDUCTION; URINE;

EID: 28444443722     PISSN: 10755535     EISSN: None     Source Type: Journal    
DOI: 10.1089/acm.2005.11.903     Document Type: Article

References (36)

1. Burzynski SR. Antineoplastons: history of the research (I). Drugs Exp Clin Res 1986;12(suppl1):1-9.
2. Badria F, Mabed M, Khafagy W, Abou-Zeid L. Potential utility of antineoplaston A-10 levels in breast cancer. Cancer Lett 2000;155:67-70.
3. Lin WC, Wu YW, Lai TY, Liau MC. Effect of CDA-II, urinary preparation, on lipofuscin, lipid peroxidation, and antioxidant systems in young and middle-aged rat brain. Am J Chin Med 2001;29:91-99.
4. Schweigerer L, Christeleit K, Fleischmann G, et al. Identification in human urine of a natural growth inhibitor for cells derived from solid pediatric tumours. Eur J Clin Invest 1992;22:260-264.
5. Masood R, McGarvey ME, Zheng T, et al. Antineoplastic urinary protein inhibits Kaposi's sarcoma and angiogenesis in vitro and in vivo. Blood 1999;93:1038-1044.
6. Vaudry D, Stork PJ, Lazarovici P, Eiden LE. Signaling pathways for PC12 cell differentiation: Making the right connections. Science 2002;296:1648-1649.
7. Cheung WM, Hui WS, Chu PW, et al. Ganoderma extract activates MAP kinases and induces the neuronal differentiation of rat pheochromocytoma PC12 cells. FEBS Lett 2000;486:291-296.
8. Chuenkova MV, Pereira MA. The T. cruzi trans-sialidase induces PC12 cell differentiation via MAPK/ERK pathway. Neuroreport 2001;12:3715-3718.
9. Cosgaya JM, Garcia-Villalba P, Perona R, Aranda A. Comparison of the effects of retinoic acid and nerve growth factor on PC12 cell proliferation, differentiation, and gene expression. J Neurochem 1996;66:89-98.
10. Sagara Y, Vanhnasy J, Maher P. Induction of PC12 cell differentiation by flavonoids is dependent upon extracellular signal-regulated kinase activation. J Neurochem 2004;90:1144-1155.
11. Lindenbaum MH, Carbonetto S, Mushynski WE. Nerve growth factor enhances the synthesis, phosphorylation, and metabolic stability of neurofilament proteins in PC12 cells. J Biol Chem 1987;262:605-610.
12. Spira AI, Carducci MA. Differentiation therapy. Curr Opin Pharmacol 2003;3:338-343.
13. Xin Y, Xu KS. HPLC determination of peptide's molecular weight in Niaoduosuantai (CDA-II) injection. Chin J Pharm anal 2001;21:191-193.
14. Shi LS. Studies on the bioactive constituents of folk medicine: Graduate Institute of Pharmaceutical Chemistry. Taichung, Taiwan, China Medical University, 2001:43-256.
15. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-1112.
16. Linder-Stragliotto C, Strander H, Munck-Wikland E, Sten-Linder M. Low levels of endostatin in the urine from patients with malignant disease. Tumour Biol 2002;23:222-227.
17. Hehir KM, Baguisi A, Pennington SE, et al. A potential anti-tumor peptide therapeutic derived from antineoplastic urinary protein. Peptides 2004;25:543-549.
18. Sloane NH, Lynn WR, Macleod RM, et al. Studies on an antineoplastic fraction from human urine. Characterization of the major protein in this fraction. Biochem J 1986;234355-362.
19. Burzynski SR. The present state of antineoplaston research (1). Integr Cancer Ther 2004;3:47-58.
20. Christman JK, Mendelsohn N, Herzog D, Schneiderman N. Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cells (HL-60). Cancer Res 1983;43:763-769.
21. Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999;21:103-107.
22. Waxman S. Differentiation therapy in acute myelogenous leukemia (non-APL). Leukemia 2000;14:491-496.
23. Matsuoka I, Mizuno N, Kurihara K. Cholinergic differentiation of clonal rat pheochromocytoma cells (PC12) induced by retinoic acid: Increase of choline acetyltransferase activity and decrease of tyrosine hydroxylase activity. Brain Res 1989;502:53-60.
24. Marshall CJ. Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation. Cell 1995;80:179-185.
25. Wang X, Studzinski GP. Activation of extracellular signal-regulated kinases (ERKs) defines the first phase of 1.25-dihydroxyvitamin D3-induced differentiation of HL60 cells. J Cell Biochem 2001;80:471-482.
26. Canon E, Cosgaya JM, Scsucova S, Aranda A. Rapid effects of retinoic acid on CREB and ERK phosphorylation in neuronal cells. Mol Biol Cell 2004;15:5583-5592.
27. Yaka R, Gamliel A, Gurwitz D, Stein R. NGF induces transient but not sustained activation of ERK in PC12 mutant cells incapable of differentiating. J Cell Biochem 1998;70:425-432.
28. Traverse S, Gomez N, Paterson H, et al. Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Comparison of the effects of nerve growth factor and epidermal growth factor. Biochem J 1992;288(pt 2):351-355.
29. Kaplan DR, Miller FD. Signal transduction by the neurotrophin receptors. Curt Opin Cell Biol 1997;9:213-221.
30. Allen LF, Sebolt-Leopold J, Meyer MB. CI-1040 (PD 184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol 2003;30:105-116.
31. Kohno M, Pouyssegur J. Pharmacological inhibitors of the ERK signaling pathway: Application as anticancer drugs. Prog Cell Cycle Res 2003;5:219-224.
32. Rinehart J, Adjei AA, Lorusso PM, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004;22:4456-4462.
33. Wang W, Waters SJ, MacDonald JR, et al. Irofulven (6- hydroxymethylacylfulvene, MGI 114)-induced apoptosis in human pancreatic cancer cells is mediated by ERK and INK kinases. Anticancer Res 2002;22:559-564.
34. Goulet AC, Chigbrow M, Frisk P, Nelson MA. Selenome-thionine induces sustained ERK phosphorylation leading to cell cycle arrest in human colon cancer cells. Carcinogenesis 2005;26:109-117.
35. Facchinetti MM, De Siervi A, Toskos D, Senderowicz AM. UCN-01-induced cell cycle arrest requires the transcriptional induction of p21(waf1/cip1) by activation of mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway. Cancer Res 2004;64:3629-3637.
36. Nguyen TT, Tran E, Nguyen TH, et al. The role of activated MEK-ERK pathway in quercetin-induced growth inhibition and apoptosis in A549 lung cancer cells. Carcinogenesis 2004;25:647-659.